Inicio / Hematología / Abstracts de hematología / Intensified treatment of…

Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)

0 / 5 (0 votos)
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)

The Lancet Haematology

Fecha de publicación: Abril de 2021

DOI: https://doi.org/10.1016/S2352-3026(21)00029-6

Autores: Sarah Gillessen, MD, Annette Plütschow, MSc, Michael Fuchs, MD, Jana Markova, MD,Prof Richard Greil, MD, Prof Max S Topp, MD, Julia Meissner, MD, Prof Josée M Zijlstra, MD,Dennis A Eichenauer, MD, Paul J Bröckelmann, MD, Prof Volker Diehl, MD, Prof Peter Borchmann, MD, Prof Andreas Engert, MD, Bastian von Tresckow, MD 

Background: To improve the long-term tumour control in early, unfavourable Hodgkin Lymphoma, the German Hodgkin Study Group (GHSG) HD14 trial compared four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with an intensified chemotherapy regimen consisting of two cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (escalated BEACOPP) plus two cycles of ABVD. The final analysis of the trial showed a significant advantage in terms of freedom from treatment failure (difference 7·2% [95% CI 3·8–10·5] at 5 years) for patients who received two cycles of escalated BEACOPP and two cycles of ABVD. However, there was no difference in overall survival between the two groups. To evaluate long-term efficacy and toxicity of this strategy, we did a follow-up analysis.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.